Pharmaceutical Research

, Volume 22, Issue 12, pp 1997–2006 | Cite as

Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b

  • Suzanne Hermeling
  • Liliana Aranha
  • J. Mirjam A. Damen
  • Monique Slijper
  • Huub Schellekens
  • Daan J. A. Crommelin
  • Wim Jiskoot
Research Paper

Purpose

This study was conducted to study the influence of protein structure on the immunogenicity in wild-type and immune tolerant mice of well-characterized degradation products of recombinant human interferon alpha2b (rhIFNα2b).

Methods

RhIFNα2b was degraded by metal-catalyzed oxidation (M), cross-linking with glutaraldehyde (G), oxidation with hydrogen peroxide (H), and incubation in a boiling water bath (B). The products were characterized with UV absorption, circular dichroism and fluorescence spectroscopy, gel permeation chromatography, reverse-phase high-pressure liquid chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, Western blotting, and mass spectrometry. The immunogenicity of the products was evaluated in wild-type mice and in transgenic mice immune tolerant for hIFNα2. Serum antibodies were detected by enzyme-linked immunosorbent assay or surface plasmon resonance.

Results

M-rhIFNα2b contained covalently aggregated rhIFNα2b with three methionines partly oxidized to methionine sulfoxides. G-rhIFNα2b contained covalent aggregates and did not show changes in secondary structure. H-rhIFNα2b was only chemically changed with four partly oxidized methionines. B-rhIFNα2b was largely unfolded and heavily aggregated. Nontreated (N) rhIFNα2b was immunogenic in the wild-type mice but not in the transgenic mice, showing that the latter were immune tolerant for rhIFNα2b. The anti-rhIFNα2b antibody levels in the wild-type mice depended on the degradation product: M-rhIFNα2b > H-rhIFNα2b ∼ N-rhIFNα2b ≫ B-rhIFNα2b; G-rhIFNα2b did not induce anti-rhIFNα2b antibodies. In the transgenic mice, only M-rhIFNα2b could break the immune tolerance.

Conclusions

RhIFNα2b immunogenicity is related to its structural integrity. Moreover, the immunogenicity of aggregated rhIFNα2b depends on the structure and orientation of the constituent protein molecules and/or on the aggregate size.

Key Words

aggregates immune tolerance immunogenicity interferon alpha2 protein structure transgenic mice 

Abbreviations

ABTS

2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)

BSA

bovine serum albumin

CD

circular dichroism

DLS

dynamic light scattering

DTT

dithiothreitol

ELISA

enzyme-linked immunosorbent assay

ESI-ToF

electrospray ionization-time of flight

GPC

gel permeation chromatography

hIFNα2

human interferon alpha2

i.p.

intraperitoneally

MALDI-ToF/ToF

matrix-assisted laser desorption ionization time of flight/time of flight

PAGE

polyacrylamide gel electrophoresis

PB

sodium phosphate buffer, pH 7.2

PBS

phosphate-buffered saline

rhIFNα2b

recombinant human interferon alpha2b

RP-HPLC

reverse-phase high-pressure liquid chromatography

s.c.

subcutaneously

SDS

sodium dodecyl sulfate

SPR

surface plasmon resonance

TFA

trifluoroacetic acid

Notes

Acknowledgments

The authors wish to thank Dr. Viscomi and Lucia Scapol for supplying the rhIFNα2b solutions, the standard anti-rhIFNα2b serum, and for valuable discussions. Dr. Pestka is kindly thanked for supplying the transgenic immune tolerant mice. Janny Westdijk is kindly acknowledged for her help with the Biacore experiments and valuable discussions. We thank Ronald van Ooijen and Georgina Gal for performing the mass spectrometric analyses. This work was financially supported by the European Union through the 5th Framework Program “Competitive and Sustainable Growth,” LYOPRO project (Contract no. G1RD-CT2002-00736).

References

  1. 1.
    Walsh, G. 2003Pharmaceutical biotechnology products approved within the European UnionEur. J. Pharm. Biopharm.55310PubMedGoogle Scholar
  2. 2.
    Hermeling, S., Crommelin, D. J. A., Schellekens, H., Jiskoot, W. 2004Structure–immunogenicity relationships of therapeutic proteinsPharm. Res.21897903PubMedCrossRefGoogle Scholar
  3. 3.
    Schellekens, H. 2002Bioequivalence and the immunogenicity of biopharmaceuticalsNat. Rev., Drug Discov.1457462CrossRefGoogle Scholar
  4. 4.
    Braun, A., Kwee, L., Labow, M. A., Alsenz, J. 1997Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic micePharm. Res.1414721478PubMedGoogle Scholar
  5. 5.
    Hochuli, E. 1997Interferon immunogenicity: technical evaluation of interferon-alpha 2aJ. Interferon Cytokine Res.17S15S21PubMedGoogle Scholar
  6. 6.
    Schernthaner, G. 1993Immunogenicity and allergenic potential of animal and human insulinsDiabetes Care16155165PubMedGoogle Scholar
  7. 7.
    Moore, W. V., Leppert, P. 1980Role of aggregated human growth hormone (hGH) in development of antibodies to hGHJ. Clin. Endocrinol. Metab.51691697PubMedGoogle Scholar
  8. 8.
    Robbins, D. C., Cooper, S. M., Fineberg, S. E., Mead, P. M. 1987Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patientsDiabetes36838841PubMedGoogle Scholar
  9. 9.
    Chackerian, B., Lowy, D. R., Schiller, J. T. 2001Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induc tion of protective autoantibodiesJ. Clin. Invest.108415423PubMedCrossRefGoogle Scholar
  10. 10.
    Bachmann, M. F., Hengartner, H., Zinkernagel, R. M. 1995T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?Eur. J. Immunol.2534453451PubMedGoogle Scholar
  11. 11.
    Fehr, T., Bachmann, M. F., Bluethmann, H., Kikutani, H., Hengartner, H., Zinkernagel, R. M. 1996T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signalCell. Immunol.168184192PubMedCrossRefGoogle Scholar
  12. 12.
    Ottesen, J. L., Nilsson, P., Jami, J., Weilguny, D., Duhrkop, M., Bucchini, D., Havelund, S., Fogh, J. M. 1994The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse modelDiabetologia3711781185PubMedGoogle Scholar
  13. 13.
    Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R., Borden, E. C., Bordens, R., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., Pestka, S. 1998Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferonsCancer Res.5824892499PubMedGoogle Scholar
  14. 14.
    Bonetti, P., Diodati, G., Drago, C., Casarin, C., Scaccabarozzi, S., Realdi, G., Ruol, A., Alberti, A. 1994Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alphaJ. Hepatol.20416420PubMedCrossRefGoogle Scholar
  15. 15.
    Palleroni, A. V., Aglione, A., Labow, M., Brunda, M. J., Pestka, S., Sinigaglia, F., Garotta, G., Alsenz, J., Braun, A. 1997Interferon immunogenicity: preclinical evaluation of interferon-alpha 2aJ. Interferon Cytokine Res.17S2327PubMedGoogle Scholar
  16. 16.
    Ryff, J. C. 1997Clinical investigation of the immunogenicity of interferon-alpha 2aJ. Interferon Cytokine Res.17S2933PubMedGoogle Scholar
  17. 17.
    Interferon alpha2b. European Pharmacopeia 5.0, Vol. 2, 2004, pp. 1812–1815.Google Scholar
  18. 18.
    Li, S., Nguyen, T. H., Schoneich, C., Borchardt, R. T. 1995Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidationBiochemistry3457625772PubMedGoogle Scholar
  19. 19.
    Peterson, G. L. 1977A simplification of the protein assay method of Lowry et al. which is more generally applicableAnal. Biochem.83346356PubMedCrossRefGoogle Scholar
  20. 20.
    ExPASy. Peptide Mass.http://ca.expasy.org/tools/peptide-mass. html (accessed 12 December 2004).
  21. 21.
    Kueltzo, L. A., Midddaugh, C. R. 2005

    Ultraviolet absorption spectroscopy

    Jiskoot, W.Crommelin, D. J. A. eds. Methods for Structural Analysis of Protein Pharmaceuticals AAPS PressArlington125
    Google Scholar
  22. 22.
    Bremer, E. T. J., Heck, A. J. R. 2005

    Mass spectrometry: protein conformational analysis and molecular recognition

    Jiskoot, W.Crommelin, D. J. A. eds. Methods for Structural Analysis of Protein PharmaceuticalsAAPS PressArlington435464
    Google Scholar
  23. 23.
    ExPASy. ExPASy Proteomics Server.http://ca.expasy.org/uniprot/Q86UP4 (accessed 1 June 2005).
  24. 24.
    Chackerian, B., Lenz, P., Lowy, D. R., Schiller, J. T. 2002Determinants of autoantibody induction by conjugated papillomavirus virus-like particlesJ. Immunol.16961206126PubMedGoogle Scholar
  25. 25.
    Fehr, T., Bachmann, M. F., Bucher, E., Kalinke, U., Padova, F. E., Lang, A. B., Hengartner, H., Zinkernagel, R. M. 1997Role of repetitive antigen patterns for induction of antibodies against antibodiesJ. Exp. Med.18517851792PubMedGoogle Scholar
  26. 26.
    Bachmann, M. F., Rohrer, U. H., Kundig, T. M., Burki, K., Hengartner, H., Zinkernagel, R. M. 1993The influence of antigen organization on B cell responsivenessScience26214481451PubMedGoogle Scholar
  27. 27.
    Phillips, W. T., Medina, L. A., Klipper, R., Goins, B. 2002A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodesJ. Pharmacol. Exp. Ther.3031116PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Suzanne Hermeling
    • 1
    • 2
  • Liliana Aranha
    • 2
  • J. Mirjam A. Damen
    • 3
  • Monique Slijper
    • 3
  • Huub Schellekens
    • 1
  • Daan J. A. Crommelin
    • 2
  • Wim Jiskoot
    • 2
  1. 1.Central Laboratory Animal InstituteUtrecht UniversityUtrechtThe Netherlands
  2. 2.Department of Pharmaceutics, Faculty of Pharmaceutical SciencesUtrecht Institute for Pharmaceutical Sciences (UIPS)UtrechtThe Netherlands
  3. 3.Department of Biomolecular Mass SpectrometryUtrecht Institute for Pharmaceutical Sciences (UIPS) and Bijvoet Center for Biomolecular ResearchUtrechtThe Netherlands

Personalised recommendations